Compare Ascendis Pharma A/S (ASND) vs Equinor ASA (EQNR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Equinor ASA — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Equinor ASA trades at $34.28 (market cap $78.18B). The key difference: Equinor ASA is far larger — about 4.4× Ascendis Pharma A/S's market cap, and Equinor ASA pays a 4.48% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | EQNR | |
|---|---|---|
Market Cap | $17.74B | $78.18B |
Sector | Health | Energy |
52-Week High | $277.18 | $42.40 |
52-Week Low | $163.32 | $22.41 |
Enterprise Value | $18.11B | $89.94B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Equinor (EQNR) trades at $33.92, down 0.26% today, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating estimates in Q4 2025 and Q1 2026 but missing in Q3 2025. Recent news highlights strategic investments in Norwegian Continental Shelf projects and a share buy-back program. Valuation ratios appear attractive with a P/E of 15.35 and EV/EBITDA of 2.27, though net income margin has declined to 5.3% in 2025 from 19.29% in 2022.
EQNR presents a value opportunity with low valuation multiples and ongoing shareholder returns via dividends and buybacks. However, declining profitability and negative net cash flow trends pose risks. Analyst sentiment is mixed with 30% buy ratings but 57% hold, suggesting cautious optimism. Key catalysts include production growth from recent investments, while oil price volatility and execution risks remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
